My first stop at the spike
Release time:
2023-07-26
One month after the peak stock was listed, that is, in August 1993, I graduated from high Secondary specialized school and entered the peak group. My working age is the age when the peak stock was listed.
My major is food technology, and I was assigned to the Maika Beverage Company under the Labor Service Company, engaged in the production of fruit and vegetable juice drinks and mineral water. At that time, there were some problems in the quality of fruit and vegetable juice drinks and mineral water, and I participated in solving practical problems as soon as I arrived. The main problem of fruit juice is fat listening, that is, the packaging expands abnormally during the shelf life, because sterilization is not complete. By strengthening the pipeline cleaning and disinfection, lengthening the sterilization time, keeping the environment clean in the filling process, and using hot filling to enhance the sterilization effect, although the fat listening situation has been reduced, it cannot be fundamentally solved. For this reason, drinks can only be sold internally and cannot be promoted to the market. In fact, we know that the root cause of the problem is that aseptic filling cannot be achieved, but because the entire production process has been finalized, it cannot be effectively solved. The packaging plastic cup and aluminum-plastic film of fruit juice beverage are disinfected by steam and ozone respectively. The so-called full-automatic filling and sealing integrated machine cannot be fully automatic. The sterilized plastic cup and aluminum-plastic film should be manually put into the designated position, and then filled and sealed by the machine. Therefore, there are at least three people in the filling room, who are respectively responsible for operating the machine, placing the plastic cup and aluminum-plastic, and cleaning the overflow beverage. In addition, the design of the production line did not consider the post-filling sterilization process, and there was not enough space to increase the process. Later, the product can only be left for one to two weeks, and then packaged and sold after eliminating fat. The problem of mineral water is flocculent precipitation, which is actually caused by the failure to aseptic filling. It can only be left for a period of time before labeling and selling unqualified products. In addition, the source of mineral water in the field, there is also a risk of pollution. Finally, these products have to go to the end.
Myka is the first stop of my work, and it is also the pain that lingers in my heart. I have always felt guilty that as a technical backbone, I can only passively deal with these problems and cannot fundamentally solve them. Looking back, the key to ensuring the quality of any product is high-quality raw materials and scientific production technology. You must be cautious in process demonstration and selection. Otherwise, it is not only a question of cost, but also a question of product survival.
1998 years later, I came to Jianfeng Pharmaceutical with regret. Everything started from scratch and began to engage in sales promotion. In fact, I am not good at communication. I can only behave with sincerity and do things seriously, slowly realize the transformation from technology to sales, and step by step into a management position. But looking back on the 30 years of work experience in the peak, the most unforgettable is Myka. Although there are regrets and lessons, I gradually grow and mature in the working atmosphere of peak harmony and tolerance. Spikes provided me with a working platform, trained me, and gave me the opportunity to display my talents in return for spikes.
The 30th anniversary of the listing of Peak Stock, the 65th anniversary of the start-up of Peak Stock, and the 70th anniversary of the start-up of a pharmaceutical company, all these resounding figures say that Peak is an excellent enterprise. Here, I sincerely wish the towering peak, the foundation everlasting, standing forever. (Xu Xianzhong, Jinhua Pharmaceutical Company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page